瑞卢戈利价格一览

Relugolix is ​​indicated for the treatment of severe menstrual bleeding caused by uterine leiomyomas and moderate to severe pain caused by endometriosis. This article will discuss the price of the original and generic drugs of Rilugoli, the listing status of the drug in the domestic market and its medical insurance reimbursement status. By analyzing these aspects, we hope to provide readers with comprehensive information and help understand the availability and economic burden of relugoli in different settings.

Prices of the original drug and generic drugs of Rilugoli

Price of the original drug

The specifications of the original drug are 40mg*100 pills per box, and the price per box is approximately US$1,096. This price can be a significant financial burden for many patients, especially if there is no insurance coverage.

Generic drug prices

Compared with original drugs, generic drugs are often available at lower prices, but as of now, we are not aware of any generic drugs of Rilugoli approved for marketing.

Factors affecting price

In addition to the production cost of the drug itself, factors such as market supply and demand, policy support, taxes, etc. will also affect the final selling price. In addition, with the advancement of technology and optimization of production processes, the price of generic drugs is expected to fall further in the future.

Relugolix’s domestic marketing status

At present, relugolix has not been officially launched in the domestic market, which means that domestic patients cannot purchase this drug directly from hospital pharmacies or local pharmacies for the time being.

Challenges of import channels

For patients who are in urgent need of treatment with relugoli, finding reliable import channels has become an option, but it also brings additional costs and risks, including transportation costs, tariffs, and uncertainty about product quality.

Future Outlook

With the opening of the pharmaceutical market and the increase in technical exchanges, it is expected that relugoli or its imitations may enter the domestic market in the next few years, bringing hope to more patients.

Rilugolix’s medical insurance reimbursement situation

Rilugolix is ​​not included in the national medical insurance reimbursement catalog, which increases the financial burden for patients who need to take this drug for a long time.

The burden of self-pay patients

Due to the lack of medical insurance support, patients have to pay the full cost of drugs, which is a heavy burden for many families, especially those who are already facing high medical expenses.

Seek other funding channels

Faced with high drug costs, some patients may seek help from charities or participate in relevant clinical trial projects to reduce financial pressure and obtain necessary treatment.